Source: Υπουργείο Υγείας (CY) Revision Year: 2019 Publisher: Remedica Ltd, Aharnon Str., Limassol Industrial Estate, 3056 Limassol, Cyprus
Remethan 100 mg prolonged-release tablets.
| Pharmaceutical Form |
|---|
|
Prolonged-release tablet. Peach, round, film-coated tablets. |
Each prolonged-release tablet contains 100 mg diclofenac sodium.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Diclofenac |
Diclofenac is a non-steroidal anti-inflammatory drug. The mechanism of action of diclofenac in AK may be related to the inhibition of the cycloxygenase pathway leading to reduced prostaglandin E2 (PGE2) synthesis. In addition, immunohistochemistry (IHC) from skin biopsies ac revealed that the clinical effects of diclofenac in AK are primarily due to anti-inflammatory, anti-angiogenic and possibly anti-proliferative effects and apoptosis-inducing mechanisms. |
| List of Excipients |
|---|
|
Core: Calcium hydrogen phosphate Coating : Titanium dioxide E171 |
PVC/Aluminium blisters. Pack sizes of 10, 30, 100 and 1000 tablets.
PP containers with PE closure. Pack sizes of 100 and 1000 tablets.
Not all pack-sizes may be marketed.
Remedica Ltd, Aharnon Str., Limassol Industrial Estate, 3056 Limassol, Cyprus
12480
Date of first authorization: 05 October 1989
Date of latest renewal: 30 September 2011
| Drug | Countries | |
|---|---|---|
| REMETHAN | Albania, Cyprus, Hong Kong, Malta, Singapore |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
